US EditionBreakthrough MS Treatment Patent Advances in Europe: BioNxt's Novel Drug Delivery System Set for Dual-Market Protection
4 Articles
4 Articles
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
VANCOUVER, BC / ACCESS Newswire / August 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE: BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce significant progress in its global patent portfolio.…
BioNxt Solutions Inc. (CSE: BNXT) (OTC Markets: BNXTF) (FWB: BXT), a bioscience company specialising in innovative drug delivery technologies, is pleased to announce an important step forward in its international patent portfolio. The company has received formal communications from both the European Patent Office (EPA) and the Eurasian Patent Organisation (EAPO) confirming that the main claims of the patent
Breakthrough MS Treatment Patent Advances in Europe: BioNxt's Novel Drug Delivery System Set for Dual-Market Protection
Novel sublingual MS treatment delivery system secures key patent acceptances in Europe and Eurasia. Innovative thin-film technology promises improved patient care. See development timeline.
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment - European Business & Finance Magazine
VANCOUVER, BC / ACCESS Newswire / August 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE: BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
